Sort   by:  
 Page size 
UnknownEverolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation.
Background Everolimus permits reduced calcineurin inhibitor (CNI) exposure, but the efficacy and safety outcomes of this treatment after kidney transplant require confirmation.Methods In a multicenter noninferiority trial, we randomized 2037 de novo kidney transplant recipients ...
S-EPMC6050928 | biostudies-literature
UnknownBacteriocin Production by Escherichia coli during Biofilm Development.
Escherichia coli is a highly versatile bacterium ranging from commensal to intestinal pathogen, and is an important foodborne pathogen. E. coli species are able to prosper in multispecies biofilms and secrete bacteriocins that are only toxic to species/strains closely related to the pr...
S-EPMC9455227 | biostudies-literature
UnknownEffects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.

Background

Sodium-glucose co-transporter-2 (SGLT2) inhibitors reduce progression of chronic kidney disease and the risk of cardiovascular morbidity and mortality in a wide range of patients. However, their effects on kidney disease progression in some patients with chronic kidney disease are...
S-EPMC7615591 | biostudies-literature
UnknownImpact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.

Background

The EMPA-KIDNEY trial showed that empagliflozin reduced the risk of the primary composite outcome of kidney disease progression or cardiovascular death in patients with chronic kidney disease mainly through slowing progression. We aimed to assess how effects of empagliflozin might...
S-EPMC7618536 | biostudies-literature
UnknownEmpagliflozin in Patients with Chronic Kidney Disease.

Background

The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range of such patients.

Methods

We enrol...
S-EPMC7614055 | biostudies-literature
UnknownThe epidemiological signature of influenza B virus and its B/Victoria and B/Yamagata lineages in the 21st century.
We describe the epidemiological characteristics, pattern of circulation, and geographical distribution of influenza B viruses and its lineages using data from the Global Influenza B Study. We included over 1.8 million influenza cases occurred in thirty-one countries during 2000-2018. We calculated t...
S-EPMC6742362 | biostudies-literature
UnknownEvaluating ChatGPT-4 for the Interpretation of Images from Several Diagnostic Techniques in Gastroenterology.
Background: Several artificial intelligence systems based on large language models (LLMs) have been commercially developed, with recent interest in integrating them for clinical questions. Recent versions now include image analysis capacity, but their performance in gastroenterology remains u...
S-EPMC11765803 | biostudies-literature
UnknownGlycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes.

Background

Data are lacking on the comparative effectiveness of commonly used glucose-lowering medications, when added to metformin, with respect to microvascular and cardiovascular disease outcomes in persons with type 2 diabetes.

Methods

We assessed the comparative effectiveness of ...
S-EPMC9832916 | biostudies-literature
UnknownPolygenic transmission disequilibrium confirms that common and rare variation act additively to create risk for autism spectrum disorders.
Autism spectrum disorder (ASD) risk is influenced by common polygenic and de novo variation. We aimed to clarify the influence of polygenic risk for ASD and to identify subgroups of ASD cases, including those with strongly acting de novo variants, in which polygenic risk is relevant. Using a novel a...
S-EPMC5552240 | biostudies-literature
UnknownLong-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.

Background

In the EMPA-KIDNEY trial, empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, had positive cardiorenal effects in patients with chronic kidney disease who were at risk for disease progression. Post-trial follow-up was designed to assess how the effects of empagliflo...
S-EPMC7616743 | biostudies-literature
Sort   by:  
 Page size